Start with the surprising number: by 2020, a striking share of the metabolic-peptide patents reaching publication were not about the GLP-1 receptor alone. They were about pairing it with a second receptor. The single-target era was already being designed out.
GLP-1 is the gut hormone that tells you you're full and helps control blood sugar. Drugs that mimic it work — but the patent filings show scientists betting that hitting GLP-1 plus a partner receptor would work better. The partner that recurs most is GIP, another incretin hormone.
Amgen's grant US10905772B2 (issued early 2021 on work filed well before) is a clean example: it covers GLP-1 receptor agonists conjugated to antagonists for the GIP receptor — deliberately engaging two arms of the incretin system in one molecule. Its companion publication US20210087286A1 describes binding proteins for the GIP receptor used in combination with GLP-1 agonists.
Aggregate that with the broader filing stream and a pattern emerges: three or more independent groups converging on multi-receptor metabolic peptides in the same window. That is the threshold where a cluster stops being noise and starts being a trend.
It is worth being precise about what this does and does not tell you. These filings predict where research money was going, not which drug would win. Correlation between filing volume and eventual market success is loose. But the direction was unambiguous — the field had decided that the future was combinations.
Read against what happened next, the 2020 map looks prescient. The drugs that reset the obesity market are multi-receptor agonists. The patent record shows that direction was set in the filings years before the prescriptions followed.